Skip to main content

TMEM16A inhibitors as a treatment option for cystic fibrosis

Ref-Nr: TA-B78025


  • TMEM16A inhibitors represent a causal treatment for cystic fibrosis
  • They reduce both excessive mucus formation and airway contraction
  • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs


It is estimated that more than 70 000 patients worldwide are suffering from cystic fibrosis (CF), a lethal genetic disorder characterized by a severe pulmonary disease caused by production a highly viscous and adherent mucus. Because CF is caused by more than 2000 different mutations, a therapy from which all patients would benefit does not exist. An ideal causal therapy for CF would reduce the excessive mucus formation as well as the airway contraction.

Bilder & Videos


Both can be achieved by using compounds that inhibit the calcium-activated chloride channel TMEM16A, which plays a crucial role in both airway smooth muscle contraction and mucus formation. Among such compounds, the FDA-approved and well-tolerated drug niclosamide and related substances have been shown to effectively reduce mucus formation in preclinical animal studies. The drugs may ideally be formulated for inhaled delivery with a spray or nebulizer.


  • TMEM16A inhibitors reduce axcessive mucus production as well as airway contraction
  • Possible repurposing of FDA-proven and well-tolerated drugs
  • Development of a drug formulation for inhalation (in form of a spray or nebulizer)

Bayerische Patentallianz GmbH

089 5480177-0
Destouchesstr. 68
80796 München


Klinischer Funktionsnachweis

Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen